Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
Roche's obesity ambition not reliant on one megablockbuster
Roche’s head of metabolic development said the company is firing “on full cylinders” to get a phase 3 trial of its GLP-1/GIP drug launched next year.
James Waldron
Sep 23, 2025 7:45am
Servier supercharges neuro pipeline with $450M deal
Sep 8, 2025 2:30am
AC Immune cuts workforce by 30%, trims pipeline to preserve cash
Sep 4, 2025 10:27am
Treeline reaps $200M series A extension, picks first 3 programs
Sep 3, 2025 11:15am
Prelude calls it curtains on lead SMARCA2 cancer asset
Aug 14, 2025 10:44am
Biohaven trashes troriluzole in OCD after ph. 3 fail
Aug 12, 2025 2:06pm
